GEN Exclusives

More »

GEN News Highlights

More »
Sep 28, 2007

Matritech and Sysmex Terminate Cervical Cancer Screening Technology Deal

  • Matritech and Sysmex mutually agreed to terminate their agreement related to use of the former’s nuclear matrix protein (NMP) associated with cervical cancer and cervical precancerous conditions. All rights licensed in the agreement thus revert to Matritech.

    The 2002 transaction granted Sysmex exclusive, worldwide rights to use NMP 179 technology for automated, nonslide-based laboratory instruments. Sysmex planned to combine the product with flow cytometry to develop an automated process to screen cervical cell specimens. 

    This discontinuation comes shortly after Inverness Medical Innovations reported intentions to purchase Matritech for $36 million in stock.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?